Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

100%(4 trials)

Phase Distribution

Ph phase_3

75%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

1(25.0%)

Phase 3Large-scale testing

3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (25.0%)

Phase 33 (75.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

NCT02633527

completedphase_3

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

NCT03247543

completedphase_3

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

NCT03247556

completedphase_3

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

NCT03247517

Clinical Trials (4)

Showing 4 of 4 trials

NCT02633527Phase 2

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Completed

NCT03247543Phase 3

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

Completed

NCT03247556Phase 3

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

Completed

NCT03247517Phase 3

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4